Claims for Patent: 8,357,714

Summary for Patent: 8,357,714

Title:	Compositions and methods for non-surgical treatment of ptosis
Abstract:	Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Inventor(s):	Silverberg; Mark (Santa Barbara, CA)
Assignee:	Voom, LLC (Santa Barbara, CA)
Application Number:	13/270,577
Patent Claims:	1. A method for treating ptosis in a subject, comprising administering an effective amount of oxymetazoline to the exterior surface of an eye of a subject in need of such treatment, wherein said effective amount essentially does not affect pupil size. 2. The method of claim 1, wherein the administering results in at least a 10 percent increase in the vertical separation of the upper and lower lids of the eye. 3. The method of claim 1, wherein the oxymetazoline is formulated as a pharmaceutical composition comprising at least 0.05 weight percent oxymetazoline in an ophthalmologically acceptable carrier. 4. The method of claim 1, wherein the oxymetazoline is provided as a pharmaceutically acceptable salt of oxymetazoline. 5. The method of claim 1, wherein the administering is administering as a single drop. 6. The method of claim 1, wherein the administering is administering at least once daily. 7. The method of claim 1, wherein the subject does not have an allergic ocular condition calling for treatment of the eye with oxymetazoline, does not have eyelid swelling, and has not undergone refractive eye surgery.